Fundraisings and IPOs

Date: 2021-03-01

Type of information: Series A financing round

Company: SalioGen Therapeutics (USA - MA)

Investors: PBM Capital (USA - VA) and other undisclosed investors

Amount: $20 Million

Funding type: series A financing round

Planned used:

  • Proceeds from the financing will be used to support the preclinical validation of the Company’s proprietary Exact DNA Integration Technology (EDIT) platform for the development of durable, safe and affordable in vivo gene therapies, including initial data in SalioGen’s lead programs in familial hypercholesterolemia and inherited macular degeneration.
  • EDIT is a genome engineering technology based on the mammal-derived enzyme saliogase. With broad applicability, the capability to deliver gene cargo of any size and significant manufacturing advantages, EDIT is used to simultaneously deliver an RNA sequence that encodes saliogase with a DNA sequence of any length to cells of interest via lipid nanoparticles. Together, the transiently expressed saliogase seamlessly integrates the supplied DNA into a precise, defined location in the recipient genome without the need for homologous recombination. SalioGen’s initial focus is on in vivo non-viral gene therapy, but EDIT also has the potential to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.


  • On March 1, 2021, SalioGen Therapeutics, a privately held biotechnology company advancing Exact DNA Integration Technology (EDIT) for non-viral gene therapy, announced that it has closed a $20 million Series A financing. The round was led by PBM Capital, a healthcare-focused investment firm, and included other undisclosed investors.
  • Concurrent with the financing, Sean Stalfort, president of PBM Capital, will join SalioGen’s Board of Directors. The Board will also include: ? Dr. Tabibiazar, CEO and chairman of SalioGen ? Joseph J. Higgins, M.D., president and chief scientific officer of SalioGen (previously at UniQure) ?  Suku Nagendran, M.D., president of R&D at Jaguar Gene Therapy (formerly the chief medical officer of Avexis)

Therapeutic area: Cardiovascular diseases - Ophthalmological diseases

Is general: Yes